Uveal Melanomas After Tumor Necrosis Factor-a Inhibitors

 

Dr. Jose Pulido, a professor of ophthalmology and molecular medicine at Mayo Clinic in Rochester, MN, expresses concern in his article appearing in the November 2014 issue of Mayo Clinic proceedings for patients who have coroidal nevi (3% of the general population) and who are being prescribed tumor Necrosis Factor-α Inhibitors. Until more is known, he recommends close ophthalmologic monitoring for that patient group.